Leading researchers at Brigham and Women's Hospital are launching a Phase I clinical trial to evaluate the safety and efficacy of a novel nasal vaccine designed to prevent and slow Alzheimer's disease progression.
This groundbreaking study, announced by the Massachusetts-based hospital, targets a disease impacting nearly 50 million people worldwide. It culminates two decades of research led by Dr. Howard L. Weiner, co-director of the Ann Romney Center for Neurologic Diseases at Brigham and a renowned neurologist with extensive experience in neurodegenerative disorders.
“Launching the first human trial of a nasal vaccine against Alzheimer's is a remarkable milestone,” Dr. Weiner stated. “Over the past two decades, our preclinical studies have demonstrated its potential. If proven safe and effective, this non-toxic approach could treat those with Alzheimer's and prevent it in at-risk individuals.”
While the exact cause of Alzheimer's remains elusive, experts widely recognize two key brain changes: beta-amyloid plaque buildup and abnormal phosphorylation and aggregation of tau proteins. These drive progressive neuron loss.
Prior studies highlight the immune system's critical role in this process.
This vaccine “activates a novel immune pathway to clear beta-amyloid plaques from the brain,” explains Dr. Tanuja Chitnis, co-director of the trial and a leading neuroimmunologist.
The vaccine centers on Protollin, an experimental intranasal agent derived from bacterial proteins. Previously used safely as an adjuvant in other vaccines to boost efficacy, Protollin is now being tested as the primary therapeutic agent.
As a Phase I trial, the focus is on assessing safety, tolerability, optimal dosing, and side effects—drawing on rigorous protocols trusted by medical authorities worldwide.
The study enrolls 16 participants aged 60-85 with early-stage Alzheimer's, who will receive two nasal doses one week apart.
